Articles
Page 3 of 20
-
Citation: BMC Pharmacology 2011 11(Suppl 1):P75
-
Metabolism of cyclic GMP in non-alcoholic fatty liver disease in morbid obesity
Citation: BMC Pharmacology 2011 11(Suppl 1):P73 -
Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):P71 -
The role of cGMP-cGKI-signaling for duodenal bicarbonate secretion
Citation: BMC Pharmacology 2011 11(Suppl 1):P69 -
Biochemical and structural characterization of C-terminal constructs of bovine soluble guanylate cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):P67 -
Does a reduction of vascular relaxation promote hypertension?
Citation: BMC Pharmacology 2011 11(Suppl 1):P64 -
Suppression of kidney fibrosis by cGMP-dependent protein kinase I
Citation: BMC Pharmacology 2011 11(Suppl 1):P62 -
Function of IRAG and the phosphorylation of the InsP3R-I for the NO/cGMP-dependent inhibition of platelet aggregation
Citation: BMC Pharmacology 2011 11(Suppl 1):P58 -
Comparative analysis of PDE10A isoforms
Citation: BMC Pharmacology 2011 11(Suppl 1):P56 -
Design and development of novel non-peptide agonists at NPR-C
Citation: BMC Pharmacology 2011 11(Suppl 1):P54 -
Protein Kinase G is a key regulator of murine white adipogenesis
Citation: BMC Pharmacology 2011 11(Suppl 1):P48 -
Cyclic GMP generated by natriuretic peptide receptor B enhances β1-adrenoceptor signaling in normal and failing hearts
Citation: BMC Pharmacology 2011 11(Suppl 1):P46 -
Nitrergic relaxation of gastrointestinal smooth muscle: role of interstitial cells of Cajal and smooth muscle cells
Citation: BMC Pharmacology 2011 11(Suppl 1):P44 -
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries –relevant to migraine?
Citation: BMC Pharmacology 2011 11(Suppl 1):P42 -
cGMP signals in smooth muscle cells and cardiac myocytes
Citation: BMC Pharmacology 2011 11(Suppl 1):P40 -
NO-sensitive guanylyl cyclase is expressed in pericytes but absent from endothelial cells in the murine lung
Citation: BMC Pharmacology 2011 11(Suppl 1):P38 -
Activation of PDE10 and PDE11
Citation: BMC Pharmacology 2011 11(Suppl 1):P36 -
Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):O32 -
New vitamin B12 derivatives activates sGC
Citation: BMC Pharmacology 2011 11(Suppl 1):P32 -
Biomarkers in two different animal models of pulmonary arterial hypertension (PAH) under treatment with a cGMP enhancing substance
Citation: BMC Pharmacology 2011 11(Suppl 1):P31 -
BNP signaling is crucial for embryonic stem cell proliferation
Citation: BMC Pharmacology 2011 11(Suppl 1):O30 -
A novel pathway of cGMP
Citation: BMC Pharmacology 2011 11(Suppl 1):O28 -
Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
Citation: BMC Pharmacology 2011 11(Suppl 1):P28 -
Specific PKG inhibitors: do they really exist?
Citation: BMC Pharmacology 2011 11(Suppl 1):P27 -
Role of a novel tetrodotoxin-resistant sodium channel in the nitrergic relaxation of rattlesnake corpus cavernosum
Citation: BMC Pharmacology 2011 11(Suppl 1):O26 -
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
Citation: BMC Pharmacology 2011 11(Suppl 1):P25 -
Cellular signaling mediated by nitrated cyclic nucleotide and regulated by hydrogen sulfide
Citation: BMC Pharmacology 2011 11(Suppl 1):O23 -
PDE expression and contractility of seminiferous tubules of the human testis
Citation: BMC Pharmacology 2011 11(Suppl 1):P23 -
High blood pressure and lost EDHF response in redox dead Cys42Ser PKGIα knock-in mouse
Citation: BMC Pharmacology 2011 11(Suppl 1):O22 -
NO signalling in synaptic transmission
Citation: BMC Pharmacology 2011 11(Suppl 1):O21 -
Interaction between bradykinin and urodilatin - a possible mechanism of clinical relevance
Citation: BMC Pharmacology 2011 11(Suppl 1):P21 -
cGMP kinase I, cardiac hypertrophy and PDE inhibition
Citation: BMC Pharmacology 2011 11(Suppl 1):O19 -
Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
Citation: BMC Pharmacology 2011 11(Suppl 1):P19 -
cGMP-PKG upregulates PGC1α and improves cardiac function in advanced cardiac hypertrophy independently of RGS2
Citation: BMC Pharmacology 2011 11(Suppl 1):O18 -
Vascular and renal function of cGMP signalling
Citation: BMC Pharmacology 2011 11(Suppl 1):O17 -
The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
Citation: BMC Pharmacology 2011 11(Suppl 1):P17 -
G-protein regulator LGN inhibits the activity of soluble guanylyl cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):P15 -
Crystal structure of cGMP-dependent protein kinase reveals novel site of interchain communication
Citation: BMC Pharmacology 2011 11(Suppl 1):O13 -
Structural insights into sGC activation by different activators
Citation: BMC Pharmacology 2011 11(Suppl 1):O11 -
Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
Citation: BMC Pharmacology 2011 11(Suppl 1):P11 -
Targeting of soluble guanylyl cyclase limits infarct size in a model of acute myocardial infarction
Citation: BMC Pharmacology 2011 11(Suppl 1):P8 -
Redox regulation of responses to hypoxia and NO-cGMP signaling in pulmonary vascular pathophysiology
Citation: BMC Pharmacology 2011 11(Suppl 1):O8 -
Nitric oxide scavenging by red cell microparticles and cell free hemoglobin as a mechanism for hemolytic diseases and the red blood cell storage lesion
Citation: BMC Pharmacology 2011 11(Suppl 1):O7 -
Conjoined NO-sensitive guanylyl cyclases
Citation: BMC Pharmacology 2011 11(Suppl 1):P6 -
Benefits of PDE5 inhibition in patients with diastolic heart failure
Citation: BMC Pharmacology 2011 11(Suppl 1):O6 -
Human genetics, natriuretic peptides and hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):O5 -
Signaling via guanylyl cyclase C: cGMP, Src and p21
Citation: BMC Pharmacology 2011 11(Suppl 1):P4 -
LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):O3 -
Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model
Citation: BMC Pharmacology 2011 11(Suppl 1):P2 -
Designer natriuretic peptides for heart failure: advanced in clinical development
Citation: BMC Pharmacology 2011 11(Suppl 1):O1